OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Jun 9, 2022 • 15min
S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs
Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.
Jun 6, 2022 • 27min
S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of older adults who develop cancer, and challenges stemming from the COVID-19 pandemic that have affected the care of geriatric patients with cancer, such as the strain put on caregivers and the shift to telemedicine.
Jun 2, 2022 • 20min
S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.
May 30, 2022 • 19min
S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challenges they experienced along the way, and advice they would share with up-and-coming oncologists based on what they know now.
May 26, 2022 • 17min
S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.
May 23, 2022 • 18min
S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.
May 19, 2022 • 14min
S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.
May 16, 2022 • 12min
S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC
Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab (Bavencio) plus axitinib (Inlyta) for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.
May 12, 2022 • 14min
S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
Dr Pegram discusses treatment sequencing in metastatic HER2-positive breast cancer, recent updates to the National Comprehensive Cancer Network guidelines, and the influence of the DESTINY-Breast03 trial on the breast cancer treatment paradigm.
May 9, 2022 • 17min
S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.
